Utah Medical Products 2Q FY26 net income falls 11.9% to USD 2.69 million; net sales drop 14.3% to USD 8.53 million
UTMD•Full-year outlook
Management projected full-year 2026 net sales to decline 10%-13% versus 2025, citing slower-than-expected new biopharma OEM customer sales.
Margins narrow on lower sales and tariffs
Operating income slid 17.1% to USD 2.65 million; operating margin narrowed 1 percentage point to 31.1%.
Gross profit edged down 15% to USD 4.76 million; gross margin tightened 0.4 percentage point to 55.8% on Filshie device tariffs.
2Q FY26 earnings and sales decline
Utah Medical Products posted 2Q 2026 net income of USD 2.69 million, down 11.9% year over year; diluted EPS fell 10.1% to USD 0.84.
Net sales dropped 14.3% to USD 8.53 million; management cited no sales to two previously largest customers.
